Evidence map›Paper›PMID 40702045›Full record

ArticleScientific reports2025

Molecular function validation and prognostic value analysis of the cuproptosis-related gene ferredoxin 1 in papillary thyroid carcinoma.

Shiyue He, Wenzhong Peng, Xinyue Hu, Yong Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Role of Ferredoxin 1Cancer pathogenesis and therapy · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shiyue He *Center of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, China.
Wenzhong Peng *Center of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, China.
Xinyue HuCenter of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, China.
Yong ChenDepartment of General Surgery, Xiangya Hospital, Central South University, Changsha, China. 178102111@csu.edu.cn.

Funding

Natural Science Foundation of Hunan Province of China 2023JJ40982Scientific Research Project of the Health Commission of Hunan Province 202203024375
6 · The paper itself

Abstract

Cuproptosis, a copper-dependent distinct form of cell death, holds a critical role in tumor development. However, further investigation is needed to elucidate the impact of the cuproptosis signaling on thyroid cancer. In this study, comprehensive bioinformatics analyses with six independent cohorts and in vitro experiments were performed to explore the expression, prognostic significance, and molecular function of the cuproptosis key regulator FDX1 in papillary thyroid carcinoma (PTC). LASSO regression analyses were utilized to screen the optimal combination of cuproptosis-related genes for constructing a Cox proportional-hazards model, and the cuproptosis-related risk score (CRRS) was calculated to stratify PTC patients in prognosis. The algorithm of ESTIMATE and ssGSEA were used to investigate the tumor immune microenvironment. Our results showed FDX1 was significantly downregulated in PTC, and its lower expression was closely associated with tumor recurrence. Based on six selected cuproptosis-related genes a predictive prognosis model was established and CRRS displayed a good prediction accuracy. Overexpression of FDX1 could promote cell death and inhibit the viability of tumor cells. Additionally, CYCS played a hub role in the cuproptosis regulatory network and could be upregulated with the overexpression of FDX1. Our study suggests that CRRS can serve as a good prognosis indicator and may provide new insights into cuproptosis-targeted therapies in PTC.

Indexed as

Thyroid Cancer, PapillaryThyroid NeoplasmsBiomarkers, TumorCell Line, TumorComputational BiologyFemaleGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansMaleMiddle AgedPrognosisTumor MicroenvironmentBiomarkers, TumorCuproptosisFDX1Papillary thyroid carcinomaPrognosis model

Identifiers

PMID40702045
PMCPMC12287535

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.